Affordable Access

deepdyve-link
Publisher Website

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.

Authors
  • Anderson, Erik S1
  • Postow, Michael A2
  • Wolchok, Jedd D2
  • Young, Robert J3
  • Ballangrud, Åse1
  • Chan, Timothy A1
  • Yamada, Yoshiya1
  • Beal, Kathryn4
  • 1 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
  • 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 3 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 4 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. [email protected]
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Oct 17, 2017
Volume
5
Issue
1
Pages
76–76
Identifiers
DOI: 10.1186/s40425-017-0282-x
PMID: 29037215
Source
Medline
License
Unknown

Abstract

Concurrent pembrolizumab with brain RT appears safe in patients with metastatic melanoma, and SRS in particular is effective in markedly reducing the size of brain metastases at the time of first follow-up MRI. These results compare favorably to SRS in combination with ipilimumab and SRS without concurrent immunotherapy.

Report this publication

Statistics

Seen <100 times